Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Drugs Fund

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

- PMLiVE

NICE says OK to Keytruda for bladder cancer via the CDF

Becomes the first immunotherapy recommended for UC after chemotherapy

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

- PMLiVE

MSD launches EU’s first biosimilar Herceptin in UK

Ontruzant is set to be strong competition for Roche’s blockbuster

- PMLiVE

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

The duo will start a series of clinical trials combining the multiple RTK inhibitor and Keytruda

Bristol-Myers Squibb (BMS) building

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

Nektar’s NKTR-214 to be paired with Opdivo and Yervoy in a host of tumour types

- PMLiVE

EC grants MSD’s Prevymis orphan product designation

The product will gain some market exclusivity benefits in CMV infection

- PMLiVE

Merck chalks up another win for Keytruda in lung cancer

Becomes the first PD-1 inhibitor to improve OS in NSCLC patients when combined with chemo

- PMLiVE

Merck closes in on adjuvant melanoma indication for Keytruda

Its immunotherapy could catch up with BMS’ Opdivo if approved

- PMLiVE

MSD’s Keytruda wins bladder cancer indication in Japan

Becomes first anti-PD1 approved in the country for previously treated UC

- PMLiVE

MSD supports Jabs for the Boys campaign

Awards HPV Action an educational grant for its HPV awareness work

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links